转移性激素敏感性前列腺癌患者年龄与联合全身治疗疗效之间的关联:系统评价与Meta分析
该系统评价与Meta分析纳入9项随机对照试验共9183例转移性激素敏感性前列腺癌患者,评估年龄(截断值70岁±5岁)对联合全身治疗总生存期的影响。结果显示多西他赛联合ADT在老年与年轻患者中均改善总生存期且无年龄差异,ARSH联合ADT在两组均改善总生存期但年轻患者获益更明显,三联疗法在无论年龄组中总生存期获益概率最高。
要点
- 多西他赛联合ADT在老年(HR 0.79)与年轻(HR 0.79)患者中均改善总生存期,无年龄差异。
- ARSI联合ADT在老年(HR 0.72)与年轻(HR 0.58)患者中均改善总生存期,年轻患者获益更明显(p=0.02)。
- 网络Meta分析治疗排序显示三联疗法在无论年龄组中总生存期获益概率最高,老年患者中三联疗法相较二联疗法的获益表达较少。
核心结论
- 转移性激素敏感性前列腺癌患者无论年龄均从联合全身治疗中获益,但年轻患者中效果更明显。
- chronological age alone seems not to be a selection criteria for the administration of combination systemic therapies.
研究设计与样本
- 系统评价、Meta分析与网络Meta分析,检索PubMed®、Web of ScienceTM和Scopus®数据库识别随机对照试验。
- 纳入分析ADT联合多西他赛和/或雄激素受体信号抑制剂(ARSI)疗效的随机对照试验,共纳入9项随机对照试验、9183例患者。
- 年龄截断值为70岁(±5岁),年轻与老年男性分别占纳入患者的51%和49%。
主要发现
- 多西他赛联合ADT显著改善老年患者总生存期(HR 0.79,95% CI 0.63-0.99,p=0.04)和年轻患者总生存期(HR 0.79,95% CI 0.69-0.90,p<0.001),无年龄差异。
- ARSI联合ADT改善老年患者总生存期(HR 0.72,95% CI 0.64-0.80,p<0.001)和年轻患者总生存期(HR 0.58,95% CI 0.51-0.66,p<0.001),年轻患者获益更多(p=0.02)。
- 网络Meta分析治疗排序显示,无论年龄组,三联疗法显示最高的总生存期获益概率;在老年患者中,三联疗法相较二联疗法的获益表达较少。
关键数值与推荐
- 年龄截断值为70岁(±5岁)。
- 多西他赛联合ADT:老年患者HR 0.79(95% CI 0.63-0.99,p=0.04),年轻患者HR 0.79(95% CI 0.69-0.90,p<0.001)。
- ARSI联合ADT:老年患者HR 0.72(95% CI 0.64-0.80,p<0.001),年轻患者HR 0.58(95% CI 0.51-0.66,p<0.001),年龄交互p=0.02。
临床怎么用
- 转移性激素敏感性前列腺癌患者无论年龄均受益于联合全身治疗。
- chronological age alone seems not to be a selection criteria for the administration of combination systemic therapies.
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combination systemic therapies have become the standard for metastatic hormone-sensitive prostate cancer (mHSPC). However, the effect of age on oncologic outcomes remains unknown. Our aim was to perform a systematic review, meta-analysis, and network meta-analysis (NMA) on the effect of chronological age on overall survival (OS) in patients treated with combination therapies for mHSPC. METHODS: We searched the PubMed®, Web of ScienceTM, and Scopus® databases to identify randomized controlled trials (RCTs) that analyzed the efficacy of combination systemic therapies using ADT plus docetaxel and/or androgen receptor signaling inhibitor (ARSI) in patients with mHSPC. We included studies, which provided separate hazard ratios (HRs) for younger vs. older patients. The selected age cut-off was 70 years (±5 years). Our outcome of interest was OS. RESULTS: We included nine RCTs with a total of 9183 patients. Younger and older men constituted 51% and 49% of included patients, respectively. Docetaxel plus ADT significantly improved OS among both older (HR 0.79, 95% CI 0.63-0.99, p = 0.04) and younger patients (HR 0.79, 95% CI 0.69-0.90, p < 0.001) with no differences according to age. ARSI plus ADT improved OS in older (HR 0.72, 95% CI 0.64-0.80, p < 0.001) and younger (HR 0.58, 95% CI 0.51-0.66, p < 0.001) patients; younger patients did benefit more (p = 0.02). On NMA treatment ranking, triplet therapy showed the highest probability of OS benefit irrespective of age group; in older patients, the benefit of triplet therapy compared to doublet was less expressed. CONCLUSIONS: Patients with mHSPC benefit from combination systemic therapies irrespective of age; the effect is, however, more evident in younger patients. Chronological age alone seems not to be a selection criteria for the administration of combination systemic therapies.
引用
- Rajwa P, Yanagisawa T, Heidegger I, et al. Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022. PMID: 36284192. doi:10.1038/s41391-022-00607-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。